# Tevogen Inc.: financial statements, quarterly

TVGN · Nasdaq · CIK 1860871 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tvgn.md) · [Financials](/companies/tvgn/financials.md) · [Filings](/companies/tvgn/filings.md) · [Insiders](/companies/tvgn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tvgn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [1.1](/filings/0001493152-24-046839.md) | [0.9 d](/filings/0001641172-25-002426.md) | [20.8](/filings/0001641172-25-010395.md) | [4.1](/filings/0001641172-25-024101.md) | [3.3](/filings/0001493152-25-022641.md) | [2.8 d](/filings/0001493152-26-014326.md) | [3.2](/filings/0001493152-26-023920.md) | [2.7](/filings/0001493152-26-038509.md) | [3.1](/filings/0001493152-25-022641.md) | [2.1 d](/filings/0001493152-26-014326.md) | [3.1](/filings/0001493152-26-023920.md) | [3.3](/filings/0001493152-26-038509.md) |
| Operating income | $m | [(2.3)](/filings/0001493152-24-046839.md) | [(2.0) d](/filings/0001641172-25-002426.md) | [(29.5)](/filings/0001641172-25-010395.md) | [(8.6)](/filings/0001641172-25-024101.md) | [(6.1)](/filings/0001493152-25-022641.md) | [(9.4) d](/filings/0001493152-26-014326.md) | [(10.4)](/filings/0001493152-26-023920.md) | [(5.4)](/filings/0001493152-26-038509.md) | [(5.7)](/filings/0001493152-25-022641.md) | [(4.6) d](/filings/0001493152-26-014326.md) | [(5.4)](/filings/0001493152-26-023920.md) | [(5.7)](/filings/0001493152-26-038509.md) |
| Interest expense | $m | [0.3](/filings/0001493152-24-046839.md) | [0.3 d](/filings/0001641172-25-002426.md) | [0.2](/filings/0001641172-25-010395.md) | not reported | [0.0](/filings/0001493152-24-046839.md) | [0.0 d](/filings/0001641172-25-002426.md) | [0.0](/filings/0001641172-25-010395.md) | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(3.9)](/filings/0001493152-24-046839.md) | [(3.6) d](/filings/0001641172-25-002426.md) | [11.3](/filings/0001493152-25-022641.md) | [(9.7)](/filings/0001493152-25-022641.md) | [(5.9)](/filings/0001493152-25-022641.md) | [(9.4) d](/filings/0001493152-26-014326.md) | [(10.4)](/filings/0001493152-26-038509.md) | [(5.5)](/filings/0001493152-26-038509.md) | [(5.7)](/filings/0001493152-25-022641.md) | [(4.7) d](/filings/0001493152-26-014326.md) | [(5.4)](/filings/0001493152-26-038509.md) | [(5.8)](/filings/0001493152-26-038509.md) |
| Diluted EPS | $ per share | [(0.03)](/filings/0001493152-24-046839.md) | not reported | [(0.26)](/filings/0001641172-25-010395.md) | [(0.04)](/filings/0001641172-25-024101.md) | [(0.03)](/filings/0001493152-25-022641.md) | not reported | [(3.25)](/filings/0001493152-26-023920.md) | [(1.71)](/filings/0001493152-26-038509.md) | [(0.03)](/filings/0001493152-25-022641.md) | not reported | [(1.61)](/filings/0001493152-26-023920.md) | [(1.52)](/filings/0001493152-26-038509.md) |
| Basic EPS | $ per share | [(0.03)](/filings/0001493152-24-046839.md) | not reported | [0.08](/filings/0001641172-25-010395.md) | [(0.04)](/filings/0001641172-25-024101.md) | [(0.03)](/filings/0001493152-25-022641.md) | not reported | [(3.25)](/filings/0001493152-26-023920.md) | [(1.71)](/filings/0001493152-26-038509.md) | [(0.03)](/filings/0001493152-25-022641.md) | not reported | [(1.61)](/filings/0001493152-26-023920.md) | [(1.52)](/filings/0001493152-26-038509.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [25.0](/filings/0001493152-23-040622.md) | [0.0](/filings/0001641172-25-002426.md) | [1.3](/filings/0001493152-24-021650.md) | [1.1](/filings/0001493152-24-032294.md) | [2.3](/filings/0001493152-24-046839.md) | [0.0](/filings/0001493152-26-014326.md) | [2.0](/filings/0001641172-25-010395.md) | [0.7](/filings/0001641172-25-024101.md) | [1.0](/filings/0001493152-25-022641.md) | [0.0](/filings/0001493152-26-014326.md) | [0.7](/filings/0001493152-26-023920.md) | [1.1](/filings/0001493152-26-038509.md) |
| Current assets | $m | [0.4](/filings/0001493152-23-040622.md) | [1.7](/filings/0001641172-25-002426.md) | [2.4](/filings/0001493152-24-021650.md) | [2.4](/filings/0001493152-24-032294.md) | [3.5](/filings/0001493152-24-046839.md) | [2.4](/filings/0001493152-26-014326.md) | [3.1](/filings/0001641172-25-010395.md) | [2.1](/filings/0001641172-25-024101.md) | [2.1](/filings/0001493152-25-022641.md) | [1.5](/filings/0001493152-26-038509.md) | [2.1](/filings/0001493152-26-023920.md) | [2.0](/filings/0001493152-26-038509.md) |
| Total assets | $m | [26.4](/filings/0001493152-23-040622.md) | [5.5](/filings/0001641172-25-002426.md) | [3.4](/filings/0001493152-24-021650.md) | [3.3](/filings/0001493152-24-032294.md) | [4.3](/filings/0001493152-24-046839.md) | [3.5](/filings/0001493152-26-014326.md) | [4.1](/filings/0001641172-25-010395.md) | [4.3](/filings/0001641172-25-024101.md) | [4.5](/filings/0001493152-25-022641.md) | [4.4](/filings/0001493152-26-038509.md) | [4.9](/filings/0001493152-26-023920.md) | [4.7](/filings/0001493152-26-038509.md) |
| Current liabilities | $m | [1.8](/filings/0001493152-23-040622.md) | [85.5](/filings/0001641172-25-002426.md) | [8.9](/filings/0001493152-24-021650.md) | [10.6](/filings/0001493152-24-032294.md) | [10.4](/filings/0001493152-24-046839.md) | [9.0](/filings/0001493152-26-014326.md) | [8.7](/filings/0001641172-25-010395.md) | [8.1](/filings/0001641172-25-024101.md) | [6.7](/filings/0001493152-25-022641.md) | [7.1](/filings/0001493152-26-038509.md) | [7.3](/filings/0001493152-26-023920.md) | [6.2](/filings/0001493152-26-038509.md) |
| Total liabilities | $m | [16.6](/filings/0001493152-23-040622.md) | [99.9](/filings/0001641172-25-002426.md) | [9.2](/filings/0001493152-24-021650.md) | [10.9](/filings/0001493152-24-032294.md) | [10.5](/filings/0001493152-24-046839.md) | [10.1](/filings/0001493152-26-014326.md) | [11.8](/filings/0001641172-25-010395.md) | [13.8](/filings/0001641172-25-024101.md) | [12.3](/filings/0001493152-25-022641.md) | [12.6](/filings/0001493152-26-038509.md) | [14.8](/filings/0001493152-26-023920.md) | [13.6](/filings/0001493152-26-038509.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(90.8)](/filings/0001493152-24-046839.md) | [(94.4)](/filings/0001493152-26-014326.md) | [(5.8)](/filings/0001493152-25-022641.md) | [(7.7)](/filings/0001493152-25-022641.md) | [(6.2)](/filings/0001493152-25-022641.md) | [(6.7)](/filings/0001493152-26-038509.md) | [(7.7)](/filings/0001493152-26-038509.md) | [(9.5)](/filings/0001493152-26-038509.md) | [(7.8)](/filings/0001493152-25-022641.md) | [(8.2)](/filings/0001493152-26-038509.md) | [(9.8)](/filings/0001493152-26-038509.md) | [(8.9)](/filings/0001493152-26-038509.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,800) d](/filings/0001493152-24-046839.md) | [(1,976) d](/filings/0001641172-25-002426.md) | [(2,164)](/filings/0001641172-25-010395.md) | [(2,983) d](/filings/0001641172-25-024101.md) | [(3,805) d](/filings/0001493152-25-022641.md) | [(3,048) d](/filings/0001493152-26-014326.md) | [(3,308)](/filings/0001493152-26-023920.md) | [(3,190) d](/filings/0001493152-26-038509.md) | [(3,650) d](/filings/0001493152-25-022641.md) | [(2,181) d](/filings/0001493152-26-014326.md) | [(2,734)](/filings/0001493152-26-023920.md) | [(3,005) d](/filings/0001493152-26-038509.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001493152-24-046839.md) | [0.0 d](/filings/0001641172-25-002426.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | [0.0 d](/filings/0001493152-23-040622.md) | [9,714 d](/filings/0001493152-24-016796.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2022 (2022-03-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [36.0](/filings/0001410578-23-001349.md) | [120](/filings/0001493152-24-021650.md) | [120](/filings/0001493152-24-032294.md) | [120](/filings/0001493152-24-046839.md) | [142](/filings/0001641172-25-010395.md) | [154](/filings/0001641172-25-024101.md) | [170](/filings/0001493152-25-022641.md) | [3.2](/filings/0001493152-26-023920.md) | [3.3](/filings/0001493152-26-038509.md) | [196](/filings/0001493152-25-022641.md) | [3.5](/filings/0001493152-26-023920.md) | [3.8](/filings/0001493152-26-038509.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 6,511,540 at 2026-08-10, from the cover of the [10-Q filed 2026-08-14](/filings/0001493152-26-038509.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.